Literature DB >> 14559816

The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of rapamycin in the response of normal fibroblasts to ionizing radiation.

Oscar M Tirado1, Silvia Mateo-Lozano, Sean Sanders, Luis E Dettin, Vicente Notario.   

Abstract

Exposure of normal mouse fibroblasts (MEF3T3) to ionizing radiation (IR) resulted in a dose-dependent increase of mTOR mRNA and protein levels and the shuttling of the mTOR protein from its normal, predominantly mitochondrial location to the cell nucleus. The same IR doses that activated mTOR induced the phosphorylation of p53 on Ser(18) (mouse equivalent to human Ser(15)) and the subsequent transcriptional activation of PUMA, a known proapoptotic p53-target gene, and promoted apoptosis involving increased overall caspase activity, caspase-3 activation, cleavage of poly(ADP-ribose) polymerase (PARP) and classic protein kinase C (PKC) isoforms, and DNA fragmentation. The proapoptotic role of mTOR in this process was demonstrated by the fact that rapamycin, a mTOR inhibitor, blocked p53 Ser(18) phosphorylation, the induction of PUMA, and all other apoptosis events. Furthermore, the proapoptotic function of mTOR was also antagonized by the expression in MEF3T3 cells of the PCPH oncoprotein, known to enhance cell survival by causing partial ATP depletion. Tetracyclin (Tet)-regulated expression of oncogenic PCPH, or overexpression of normal PCPH, blocked both phosphorylation and nuclear shuttling of mTOR in response to IR. These results indicate that alterations in PCPH expression may render tumor cells resistant to IR, and perhaps other DNA-damaging agents, by preventing mTOR activation and signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559816

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation.

Authors:  Jennifer Blickwedehl; Scott Olejniczak; Ryan Cummings; Nilofar Sarvaiya; Ana Mantilla; Asher Chanan-Khan; Tej K Pandita; Marion Schmidt; Craig B Thompson; Naveen Bangia
Journal:  Mol Cancer Res       Date:  2012-05-01       Impact factor: 5.852

2.  Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage.

Authors:  Emiliano Panieri; Gabriele Toietta; Marina Mele; Valentina Labate; Sofia Chiatamone Ranieri; Salvatore Fusco; Valentina Tesori; Annalisa Antonini; Giuseppe Maulucci; Marco De Spirito; Tommaso Galeotti; Giovambattista Pani
Journal:  Aging (Albany NY)       Date:  2010-08       Impact factor: 5.682

3.  Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53.

Authors:  Chung-Han Lee; Ken Inoki; Magdalena Karbowniczek; Emmanuel Petroulakis; Nahum Sonenberg; Elizabeth Petri Henske; Kun-Liang Guan
Journal:  EMBO J       Date:  2007-10-25       Impact factor: 11.598

4.  PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.

Authors:  Joaquín Villar; Humair S Quadri; Insun Song; York Tomita; Oscar M Tirado; Vicente Notario
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

5.  mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.

Authors:  Matthew J Schiewer; Robert Den; David T Hoang; Michael A Augello; Yaacov R Lawrence; Adam P Dicker; Karen E Knudsen
Journal:  Endocr Relat Cancer       Date:  2012-01-09       Impact factor: 5.678

Review 6.  NTPDase5/PCPH as a new target in highly aggressive tumors: a systematic review.

Authors:  Paula Andreghetto Bracco; Ana Paula Santin Bertoni; Márcia Rosângela Wink
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

7.  DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1.

Authors:  Jogitha Selvarajah; Androulla Elia; Veronica A Carroll; Abdeladim Moumen
Journal:  Oncotarget       Date:  2015-01-01

8.  ENTPD5: identification of splicing variants and their impact on cancer survival.

Authors:  Rafael Paschoal de Campos; Marcia Rosângela Wink; Guido Lenz
Journal:  Purinergic Signal       Date:  2021-06-02       Impact factor: 3.765

9.  The ENTPD5/mt-PCPH oncoprotein is a catalytically inactive member of the ectonucleoside triphosphate diphosphohydrolase family.

Authors:  Caitlin M MacCarthy; Vicente Notario
Journal:  Int J Oncol       Date:  2013-08-06       Impact factor: 5.650

Review 10.  Modulation of ERQC and ERAD: A Broad-Spectrum Spanner in the Works of Cancer Cells?

Authors:  Gábor Tax; Andrea Lia; Angelo Santino; Pietro Roversi
Journal:  J Oncol       Date:  2019-10-01       Impact factor: 4.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.